N/A N=27 Evaluation of Atorvastatin on Atherosclerosis Composition
Atherosclerosis
Primary: Change in Necrotic Core Volume — 0.07 mm^2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=2,584 Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function
Iron Deficiency Anemia · Impaired Renal Function
Primary: Mean Change From Baseline to the Highest Observed Hemoglobin Any Time From Baseline to End of Study. — 1.13; 0.92 g/dL
Phase 2 N=11 Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Liver Cancer
Primary: Number of Subjects Experiencing Adverse Events — 2 participants
N/A N=144 Prospective Study of an Investigational Toric Soft Contact Lens
Myopia · Astigmatism · Refractive Error
Primary: Contact Lens-Corrected Distance Monocular Snellen Visual Acuity (VA) (20/30 or Better) — 98.9; 98.9; 98.9; 97.8 Percentage of eyes
Phase 2 N=19 A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant Patients
Liver Transplantation
Primary: Area Under the Concentration-time Curve From Time 0 to 24 Hours (AUC0-24) for Tacrolimus — 198.2; 193.0 ng*hr/mL
Phase 2 N=218 BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Best Objective Response — 13.0 percentage of participants
N/A N=416 GLYCOSA Study:Effect of PAP Treatment on Glycemic Control in Patients With Type 2 Diabetes
Diabetes Mellitus Type 2
Primary: HbA1c Change — -0.1; -0.1 HbA1c percent
Phase 2 N=29 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab
Breast Neoplasms
Primary: Objective Response (OR) — 80.0; 75.0; 36.4 Percentage of participants
Phase 2 N=29 Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer
Prostate Cancer
Primary: Overall Clinical Benefit of Tarceva in CRPC. — 36 percentage of pts w/clinical benefit
Phase 3 N=241 Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
Diabetes Mellitus, Type 2
Primary: HbA1c Change From Baseline to Week 12 — -0.11; -0.53 Percent — p=<0.0001
Phase 1 N=18 Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.
Breast Neoplasms
Primary: Number of Participants With Dose Limiting Toxicities (DLT) — 4; 2 Participants
Phase 2 N=319 Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
HIV Infections · Sexually Transmitted Diseases
Primary: Percentage of Participants With HPV6 Antibody Development From Seronegative Status at Baseline to Seropositive Status a Month After Completion of HPV Vaccination Series…
N/A N=345 Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans
Drug Dependence
Primary: Percentage of Participants Meeting Diagnosis of Opioid Dependence on Composite International Diagnostic Interview-2 (CIDI-2) — 20; 21 percentage of opioid dependent…
Phase 1 N=31 Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
MDS · AML · Solid Tumors
Primary: Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours Post-dose — 455.86; 897.43; 921.87; 1502.86 ng*hr/mL
Phase 3 N=148 Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients
Multiple Sclerosis
Primary: Change From Week 2 to Week 6 in Composite Score of Patient Satisfaction With Injection Experience — 4.1; 4.8; 0.7 units on a scale — p=<0.0001